

# Vibrio, Aeromonas, Campylobacter, and Helicobacter

Dr Esraa Al-Fraihat MD - University of Jordan School of Medicine | Clear printable mind map

## 0) Big Picture: Where they live + what they cause

### Shared opening idea

• All are Gram-negative rods widely distributed in nature. • They are studied together because many are water/animal-associated GI pathogens.

### Reservoirs / natural habitat

• Vibrios: marine and surface waters. • Aeromonads: fresh and brackish waters. • Campylobacters: animals, especially domesticated animals. • Helicobacters: GI and hepatobiliary tracts of humans and mammals; also chickens and wild birds.

### Major clinical anchors

• V. cholerae: cholera - profuse watery diarrhea -> dehydration/death. • C. jejuni: common cause of enteritis in humans. • H. pylori: gastritis and duodenal ulcer disease.

## Master map: organism -> habitat -> most tested clue

Organism group	Most important habitat/source	High-yield lab/clinical clue
Vibrio	Marine/surface water; contaminated water/food; seafood	Comma-shaped, oxidase+, polar flagella, halophilic; V. cholerae yellow on TCBS; cholera toxin -> cAMP watery diarrhea
Aeromonas	Fresh/brackish water; food/water; traumatic wound exposure	Oxidase+ Gram-negative rods resembling Enterobacteriaceae; often beta-hemolytic on blood agar
Campylobacter	Poultry, cattle, sheep, pigs, birds, pet dogs	Microaerophilic, grows best at 42 C, gull-wing rods, darting motility; C. jejuni hippurate+
Helicobacter pylori	Humans mainly; gastric mucous layer	Spiral Gram-negative rod, catalase+, oxidase+, urease+; causes chronic gastritis/ulcers/cancer risk

# 1) The Vibrios + Vibrio cholerae: morphology and identification

## A) The Vibrios - general properties

### Shape + basic tests

• Comma-shaped, facultatively anaerobic rods.  
• Catalase positive and oxidase positive.  
• Most species are motile by polar flagella.

### Growth requirements

• Broad temperature range: 14-40 C.  
• High pH range: 8.5-9.5.  
• Require sodium chloride for growth - halophilic, meaning salt-loving.

### Important species

• V. cholerae O1 and O139 cause cholera in humans.  
• V. parahaemolyticus and V. vulnificus can cause skin/soft tissue infections, sepsis, or gastroenteritis.  
• Cholera is associated with poor sanitation and contaminated water/food.

## B) V. cholerae - morphology and identification

### Culture and appearance

• Comma-shaped, curved, motile rod.  
• Grows well at 37 C on routine media and selective TCBS agar.  
• V. cholerae produces yellow colonies on TCBS because it ferments sucrose.

### TCBS color contrast

• V. cholerae: sucrose fermenter -> yellow colonies.  
• V. parahaemolyticus and V. vulnificus: non-sucrose fermenters -> green colonies.

### Specimen timing

• Stool specimens should be collected early in diarrheal illness.  
• In endemic areas, stool culture on TCBS plus enrichment broth culture are appropriate.

### Biochemical pattern

• Regularly ferments sucrose and mannose but not arabinose.  
• Oxidase positive.  
• Can grow on most agar media without additional salt.

### O antigen serogroups

• V. cholerae has O LPS antigen with about 200 serogroups.  
• O1 and O139 cause epidemic and pandemic cholera.  
• Non-O1/non-O139 can cause cholera-like diarrheal disease.

### O1 serotypes and biotypes

• O1 serotypes: Ogawa, Inaba, Hikojima.  
• Two epidemic O1 biotypes: classic and El Tor.  
• El Tor produces hemolysin and is resistant to polymyxin B.

### Capsules

• O139, non-O1 V. cholerae strains, and V. vulnificus produce acidic polysaccharide capsules.  
• V. cholerae O1 does not produce this capsule.

# 2) Vibrio cholerae: toxin, disease, diagnosis, treatment, epidemiology

## A) Cholera toxin + pathogenesis

Enterotoxin structure/action	Mechanism of diarrhea	Pathologic result
<ul style="list-style-type: none"> <li>Heat-labile enterotoxin made of A and B subunits.</li> <li>B subunits bind GM1-ganglioside receptor on enterocyte membrane.</li> <li>A1 subunit increases intracellular cAMP.</li> </ul>	<ul style="list-style-type: none"> <li>A1 ADP-ribosylates the stimulatory G protein and locks it active.</li> <li>Persistent adenylate cyclase activation -&gt; increased cAMP.</li> <li>cAMP drives active secretion of Na, Cl, K, bicarbonate, and water into intestinal lumen.</li> </ul>	<ul style="list-style-type: none"> <li>Prolonged hypersecretion of water and electrolytes.</li> <li>Electrolyte-rich diarrhea can reach 20-30 L/day.</li> <li>Can cause dehydration, shock, acidosis, and death.</li> </ul>
Attachment and toxins	Host/source/risk	
<ul style="list-style-type: none"> <li>Organisms attach to epithelial microvilli.</li> <li>They multiply and liberate cholera toxin.</li> <li>They may also liberate mucinases and endotoxin.</li> </ul>	<ul style="list-style-type: none"> <li>Pathogenic only for humans.</li> <li>Can grow with copepods and zooplankton.</li> <li>Contaminated food and water are the more likely source of infection.</li> <li>Achlorhydria/hypochlorhydria or PPI use lowers infectious dose: about <math>10^3</math> instead of <math>10^{10}</math>.</li> </ul>	

## B) Clinical findings

Disease spectrum	Classic symptoms
<ul style="list-style-type: none"> <li>Ranges from asymptomatic intestinal colonization to severe diarrhea.</li> <li>Incubation period: 12 hours to 3 days depending on inoculum size.</li> </ul>	<ul style="list-style-type: none"> <li>Sudden nausea and vomiting.</li> <li>Then profuse diarrhea with abdominal cramps.</li> <li>Rice-water stool.</li> </ul>
Severe cholera	Biotype and immunity
<ul style="list-style-type: none"> <li>Fluid loss can reach 1 L/hour.</li> <li>Dehydration can lead to shock and collapse.</li> <li>Mortality 25-50% untreated; reduced to about 1% with early fluid replacement.</li> </ul>	<ul style="list-style-type: none"> <li>V. cholerae O1 El Tor tends to cause milder disease than classic biotype.</li> <li>Attack of cholera is followed by immunity to reinfection, but duration/degree are not known.</li> <li>Serum vibriocidal antibodies titer <math>\geq 1:20</math> are associated with protection; antitoxin antibodies are not protective.</li> </ul>

# 3) Vibrio cholerae: laboratory tests, treatment, prevention + other Vibrios

## A) Diagnostic laboratory tests

### Specimens and transport

• Stool specimens collected early in diarrheal illness.  
• Inoculate within 2-4 hours of collection.  
• If delayed, mix in Cary-Blair transport medium.

### Microscopy clue

• Dark-field or phase-contrast microscopy shows motility.  
• Shooting star motility after mixing with polyvalent O1 antisera suggests *V. cholerae* O1.

### Culture

• Grows well on most agar media.  
• Rapid growth in alkaline peptone broth/water containing 1% NaCl at pH 8.5.  
• Also grows on TCBS agar.

### Confirmation

• Slide agglutination using anti-O group 1 or group 139 antisera.  
• Biochemical reaction patterns complete identification.

## B) Treatment, prevention, and epidemiology

### Treatment priority

• Water and electrolyte replacement is the most important step.  
• It corrects severe dehydration and salt depletion.

### Antimicrobials

• Appropriate antimicrobial therapy reduces duration and stool shedding.  
• Effective: tetracycline, TMP-SMX, fluoroquinolones, doxycycline.  
• Children/pregnancy: erythromycin and/or azithromycin are appropriate choices.

### Pandemics and spread

• Seven pandemics since 1817 have been recorded.  
• Caused by classic O1 biotype except the seventh, which is O1 El Tor.  
• Spread by mildly/early ill individuals, water, food, and flies.  
• Only 1-5% of exposed susceptible persons develop disease.

### Carriage and control

• Infected people shed only during first few days of illness.  
• No long-term carriage in humans; seldom exceeds 3-4 weeks.  
• Prevention: education, improved sanitation, patient isolation, disinfection.  
• Antimicrobial treatment reduces symptoms and transmission; chemoprophylaxis for household contacts can limit spread.  
• Cholera vaccines are available and advised for travel to endemic areas.

## C) Non-O1 / non-O139 *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus*

### Non-O1 and non-O139 *V. cholerae*

• Generally not associated with classic epidemic cholera.  
• Can cause mild diarrhea, cholera-like diarrhea, wound infection, or septicemia.  
• Associated with contaminated water, seafood, or environmental exposure.  
• Some strains produce toxins/virulence factors but usually lack classic O1/O139 + cholera toxin epidemic combination.  
• Important in patients with comorbidities or aquatic exposure.

### *V. parahaemolyticus*

• Halophilic *Vibrio* associated with marine environments.  
• Usually follows raw/undercooked seafood, especially shellfish.  
• Acute gastroenteritis: watery diarrhea, cramps, nausea, vomiting, sometimes fever.  
• Some cases have dysentery-like features.  
• Diagnosis by stool culture with appropriate selective methods; illness usually self-limited.

### *V. vulnificus*

• Halophilic *Vibrio* associated with seawater and shellfish, especially oysters.  
• Infection via contaminated raw oysters or wound exposure to seawater.  
• GI symptoms may be followed by rapidly progressive septicemia.  
• Wound infection can progress to cellulitis, bullae, necrotizing fasciitis, and septic shock.  
• Severe disease risk: liver disease, alcoholism, hemochromatosis, immunosuppression, chronic illness.

# 4) Aeromonas and Campylobacter

## A) Aeromonas

### Basic features and habitat

• Ubiquitous inhabitants of fresh and brackish water. • Gram-negative, facultative anaerobic rods. • Ferment carbohydrates and may resemble Enterobacteriaceae. • Key difference: Aeromonas are oxidase-positive.

### Culture and species

• Grow on blood agar and enteric differential/selective agars. • On blood agar they are usually beta-hemolytic. • Main human species: *A. hydrophila*, *A. caviae*, *A. veronii* biovar *sobria*.

### Gastroenteritis

• *A. caviae* is most frequently associated with gastroenteritis. • Ranges from watery diarrhea to dysentery-like illness. • Associated symptoms: abdominal pain, fever, nausea, vomiting. • Follows ingestion of contaminated food or water, especially warm summer months. • Usually self-limited; severe diarrhea/dehydration or children may require hospitalization.

### Extraintestinal disease

• *A. hydrophila* causes wound infections after traumatic injury exposed to fresh/brackish water. • Cellulitis usually develops within 48 hours. • Fasciitis, myonecrosis, osteomyelitis, and systemic symptoms may occur. • Soft tissue infection may rarely follow medicinal leech use. • Sepsis mostly due to *A. hydrophila*, mainly in hematologic malignancy and/or liver disease.

### Diagnosis and treatment

• Suggested by Gram-negative rods, oxidase positivity, growth on blood/enteric agars, and usually beta-hemolysis. • Gastroenteritis usually needs no antimicrobials; severe cases may improve faster with treatment. • Clinically significant aeromonads resist penicillin and ampicillin; often resist cefazolin and ticarcillin. • Active options: 3rd-gen cephalosporins, aztreonam, carbapenems, aminoglycosides, especially fluoroquinolones. • Empiric therapy may use two or more agents until susceptibility results are available.

## B) Campylobacter - culture, diagnosis, disease, treatment, epidemiology

### Culture requirements

• Requires microaerobic atmosphere: reduced O<sub>2</sub> 5-7% and increased CO<sub>2</sub> 10% for optimal growth. • Most grow best at 42 C; growth can be seen between 36 C and 42 C. • Primary plates for *C. jejuni* isolation should be incubated at 42 C.

### Selective medium and colonies

• Skirrow medium contains vancomycin, polymyxin B, and trimethoprim to inhibit other bacteria. • Colonies are generally colorless or gray. • May be watery/spreading or round/convex. • No hemolysis on blood-containing agar.

### Biochemical/microscopy clues

• *C. jejuni* and *C. coli* are oxidase-positive and catalase-positive. • Campylobacters do not oxidize or ferment carbohydrates. • Gram stain: gull-wing-shaped rods. • Dark-field/phase-contrast: darting motility. • Culture on selective media is definitive for *C. jejuni* enteritis. • Positive hippurate hydrolysis distinguishes *C. jejuni* from other Campylobacter species.

### Disease

• Acquired orally from contaminated food, drink, poultry, or contact with infected animals. • Multiply in small intestine, invade epithelium, cause inflammation with RBCs and WBCs in stool. • *C. jejuni* and *C. coli*: most commonly gastroenteritis. • *C. fetus*: bacteremia and extraintestinal infections in pregnant women and immunocompromised patients. • *C. jejuni* gastroenteritis: crampy abdominal pain, profuse diarrhea that may be bloody, headache, malaise, fever.

### Treatment and complications

• Illness is usually self-limited for 5-8 days. • Recurrence occurs in about 5-10% of patients. • Most cases resolve without antimicrobials. • Macrolides, especially erythromycin, may be used and shorten fecal shedding. • Postdiarrheal complications: Guillain-Barre syndrome, reactive arthritis, Reiter syndrome.

### Reservoirs

• Reservoirs include poultry, cattle, sheep, pigs, birds, and pet dogs depending on species.

# 5) Helicobacter pylori

## A) Features, identification, and pathogenesis

### Basic features

• Spiral-shaped Gram-negative rod.  
• Catalase-positive, oxidase-positive, and urease-positive.  
• Motile with single and/or multiple monopolar, typically sheathed flagella.  
• Humans are the primary host-reservoir.

### Associated diseases

• Antral gastritis.  
• Duodenal peptic ulcer disease.  
• Gastric ulcers.  
• Gastric adenocarcinoma.  
• Gastric MALT lymphoma.

### Culture identification

• Can be isolated from gastric biopsy specimens.  
• Requires 37 C, microaerophilic humid atmosphere, usually 3-6 days incubation.  
• If culture is negative, incubate up to 14 days.  
• Primary isolation uses enriched media with blood/blood products such as chocolate agar, or antibiotic-containing media such as Skirrow medium.  
• Colonies on blood agar range from gray to translucent.

### Urease function

• Urease breaks urea into ammonia and CO2.  
• This helps neutralize gastric acid and supports survival in the stomach.

### Colonization and movement

• Colonizes gastric-type epithelial cells.  
• Found deep in the mucous layer near epithelial surface.  
• Flagella-mediated motility allows movement through gastric mucus toward epithelium.

### Virulence factors and inflammation

• Tissue damage relates to mucinase, phospholipase, neutrophil-activating protein A, heat shock protein 60, CagA, and VacA.  
• CagA induces IL-8 -> neutrophil attraction.  
• VacA affects cell death/proliferation and activates IL-8-mediated acute inflammation.  
• Histology: acute and chronic inflammation with polymorphonuclear and mononuclear infiltrates.  
• Antimicrobial therapy clears H. pylori and improves gastritis and duodenal ulcer disease.

## B) Clinical findings and diagnosis

### Clinical findings

• Acute infection causes upper GI illness with nausea and pain.  
• Vomiting and fever may also occur.  
• Symptoms last less than 1 week to 2 weeks.  
• After acute infection, colonization may persist for years, decades, or lifelong.  
• About 90% of duodenal ulcer patients and 50-80% of benign gastric ulcer patients have H. pylori infection.  
• Long colonization is associated with chronic gastritis, intestinal metaplasia, atrophic gastritis, and gastric adenocarcinoma.

### Specimens and histology/culture

• Gastric biopsy specimens are used for histology or culture.  
• Blood is used for serum antibodies.  
• Stool is used for H. pylori antigen detection.  
• Histology is generally more sensitive than culture.  
• Hematoxylin and eosin show acute/chronic gastritis.  
• Giemsa, silver, or immunohistochemical stains show curved or spiral organisms.  
• Culture is mainly for patients not responding to treatment when susceptibility testing is needed.

# 6) H. pylori: tests, treatment, epidemiology + final comparison

## A) Serology and other diagnostic tests

Antibodies	Active infection tests	Immunity
<ul style="list-style-type: none"> <li>IgG antibodies confirm exposure, but titers do not correlate with disease severity.</li> <li>IgM disappears rapidly and has little diagnostic value.</li> <li>IgA and IgG persist after eradication, so antibody testing has limited value for active infection or cure.</li> </ul>	<ul style="list-style-type: none"> <li>Histology of gastric biopsy: 95-100% sensitivity and specificity.</li> <li>Rapid urease test detects urease activity within 1-2 hours by pH color change.</li> <li>Urea breath test detects labeled CO<sub>2</sub> after 13C- or 14C-labeled urea; sensitivity/specificity 94-98%.</li> <li>Stool antigen ELISA diagnoses active infection and is useful as a test of cure.</li> </ul>	<ul style="list-style-type: none"> <li>Infection induces IgM first.</li> <li>Persistent IgG and IgA occur in chronic infection.</li> </ul>

## B) Treatment

Triple therapy 7-14 days	Alternative quadruple therapy 10-14 days	Important notes
<ul style="list-style-type: none"> <li>PPI twice daily.</li> <li>Amoxicillin 1 g twice daily.</li> <li>Clarithromycin 500 mg twice daily.</li> </ul>	<ul style="list-style-type: none"> <li>PPI.</li> <li>Metronidazole 250 mg four times daily.</li> <li>Tetracycline 500 mg four times daily.</li> <li>Bismuth.</li> </ul>	<ul style="list-style-type: none"> <li>Fourteen-day regimens eradicate H. pylori in 70-95% of patients.</li> <li>PPIs directly inhibit H. pylori and act as potent urease inhibitors.</li> <li>Recurrent/persistent infection may require tailored therapy for antimicrobial-resistant strains.</li> </ul>

## C) Epidemiology and control

Reservoir and transmission	Prevalence	Spread evidence/control
<ul style="list-style-type: none"> <li>Humans are likely the primary, if not sole reservoir.</li> <li>Transmission is mainly oral-oral and/or fecal-oral.</li> <li>Infection usually acquired in early childhood and may persist lifelong without antibiotics.</li> </ul>	<ul style="list-style-type: none"> <li>Higher in developing countries.</li> <li>In Southeast Asia, adult prevalence may reach up to 90%.</li> <li>In the United States: fewer than 20% in persons younger than 30 years; increases to 40-60% in those 60 years and older.</li> </ul>	<ul style="list-style-type: none"> <li>Person-to-person spread supported by intrafamilial clustering.</li> <li>Rare transmission occurs via improperly cleaned endoscopes.</li> </ul>

## Final high-yield comparison table

Organism	Key clue	Disease anchor	Diagnosis anchor	Treatment anchor
V. cholerae	Comma-shaped; oxidase+; yellow on TCBS; O1/O139 epidemic	Rice-water stool, massive watery diarrhea, dehydration	Early stool; TCBS; alkaline peptone; shooting-star motility; O1/O139 antisera	Fluids/electrolytes first; tetracycline, doxycycline, TMP-SMX, fluoroquinolone; azithro/erythro in children/pregnancy
V. parahaemolyticus	Halophilic marine Vibrio; green on TCBS as non-sucrose fermenter	Seafood gastroenteritis, sometimes dysentery-like	Stool culture with selective methods	Usually self-limited
V. vulnificus	Seawater/oysters; high risk with liver disease/iron overload/immunosuppression	Septicemia; wound cellulitis, bullae, necrotizing fasciitis, shock	Exposure + culture/clinical suspicion	Urgent antimicrobial/surgical management as severe infection
Aeromonas	Fresh/brackish water; oxidase+; beta-hemolytic	Gastroenteritis; wounds after water trauma; sepsis in liver disease/hematologic malignancy	Gram-negative rod + oxidase+ + blood/enteric growth + beta-hemolysis	Usually no antibiotics for gastroenteritis; severe: fluoroquinolones, 3rd-gen cephalosporins, etc.
Campylobacter jejuni	Microaerophilic; 42 C; gull-wing rods; darting motility; hippurate+	Bloody/profuse diarrhea, cramps, fever; GBS/reactive arthritis/Reiter later	Selective culture definitive; Skirrow medium; oxidase/catalase+	Mostly self-limited; erythromycin/macrolide may shorten shedding
H. pylori	Spiral; catalase+, oxidase+, urease+; gastric mucus	Gastritis, duodenal/gastric ulcer, gastric adenocarcinoma, MALT lymphoma	Histology, rapid urease, urea breath, stool antigen; culture mainly for treatment failure	Triple or quadruple therapy with PPI-based regimen